Capricor Therapeutics, Inc. (CAPR) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript [Seeking Alpha]
Capricor Therapeutics, Inc. (CAPR)
Last capricor therapeutics, inc. earnings: 3/18 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
capricor.com/investors
Company Research
Source: Seeking Alpha
Linda Marbán - Co-Founder, President, CEO & Director Anthony Bergmann - CFO & Corporate Treasurer Conference Call Participants William Han Presentation William Han Everyone. Thank you for joining. By way of quick introduction, I'm Will Han, Senior VP of Biotech Investment Banking. I'm thrilled today to welcome Linda Marbán, CEO of Capricor and A.J. Bergmann, CFO of Capricor. As a quick background on Linda and A.J. as well as Capricor, Linda is Co-Founder of Capricor, has served as CEO since 2010. Linda has been in the biotech field for over 20 years and prior to Capricor held various senior roles at Excigen, a gene therapy biotech company. A.J. has served as Capricor's CFO since 2018 and has been in the biotech industry for 15 years, joined the company in 2011. Capricor is a late-stage biotech company developing deramiocel, allogeneic cardiac-derived cell therapy that has filed for approval for the treatment of Duchenne's muscular dystrophy, PDUFA date of August 22, 202
Show less
Read more
Impact Snapshot
Event Time:
CAPR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CAPR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CAPR alerts
High impacting Capricor Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
CAPR
News
- Capricor Therapeutics (CAPR) was upgraded by LADENBURG THALM/SH SH to "strong-buy".MarketBeat
- Capricor's Positive 5-Year Data For DMD Treatment Comes With A Regulatory Catch – CAPR Stock Slides 11% [Yahoo! Finance]Yahoo! Finance
- Capricor Therapeutics Announces FDA Advisory Committee Meeting to Review BLA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy [Yahoo! Finance]Yahoo! Finance
- Capricor Therapeutics Announces FDA Advisory Committee Meeting to Review BLA for Deramiocel for the Treatment of Duchenne Muscular DystrophyGlobeNewswire
- Capricor to Present Positive Five-Year HOPE-2 OLE Data and HOPE-3 Phase 3 Results for Deramiocel in Duchenne Muscular Dystrophy at PPMD 2026 Annual ConferenceGlobeNewswire
CAPR
Earnings
- 5/12/26 - Miss
CAPR
Analyst Actions
- 5/13/26 - HC Wainwright
CAPR
Sec Filings
- 6/29/26 - Form 4
- 6/29/26 - Form 4
- 6/26/26 - Form 8-K
- CAPR's page on the SEC website